Search
for

    Research

    5 / 1000+ results

    Community Join

    5 / 23 results

    Learn

    3 / 801 results

      learn HMI-115

      much-hyped research compound targeting prolactin receptor in scalp
      • HMI-115: Frequently Asked Questions About Hair Loss Treatment HMI-115 is an investigational anti-prolactin-receptor antibody being trialled for androgenetic alopecia. It is not approved anywhere; its hair-loss evidence is a 16-person Phase 1b announced only by press release, plus a completed 192-man Phase 2 in China whose results are not yet published.
      • What is HMI-115 and how is it different from common treatments like minoxidil? HMI-115 (BAY 1158061) is an investigational monoclonal antibody that blocks the prolactin receptor, not a GnRH antagonist. It is given by injection in trials and is not approved anywhere; minoxidil is an approved topical vasodilator with decades of published data, while HMI-115's hair-loss trial results remain unpublished.
      • Is HMI-115 considered a safe option, or does it have strong side effects? HMI-115 is an experimental injected antibody, not a hormone blocker: the one published trial (in endometriosis) reported an acceptable 12-week tolerability profile with no treatment-related serious adverse events, and no peer-reviewed safety data exists for its use in hair loss.

      learn Osteopontin

      signaling protein that, when suppressed, may grow hair by reducing inflammation and stem cell loss